← Back to Search

Brain Stimulation

Home-Based Brain Stimulation for Post-COVID Syndrome

N/A

Recruiting

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

A diagnosis of PASC as indicated by past COVID-19 infection, and persistent symptoms, including 'brain fog', confusion, short-term memory deficits, trouble concentrating, delirium, difficulties in multitasking.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 weeks

Awards & highlights

Study Summary

This trial is testing whether tDCS can help improve attention and processing speed in people who have experienced long-term effects of COVID-19.

Who is the study for?

This trial is for individuals who have had COVID-19 and are now experiencing persistent symptoms like 'brain fog', confusion, memory issues, concentration problems, or delirium. Candidates must be able to consent and not have a major neurological condition before COVID-19, metal implants in the head/neck area, brain stimulators, epilepsy history, pacemakers, active substance dependence (except tobacco), ADHD or severe mental illness.Check my eligibility

What is being tested?

The study tests if home-based transcranial direct current stimulation (tDCS) can improve cognitive functions such as attention and processing speed in patients with post-COVID conditions. Participants will receive either an active tDCS treatment or a sham (placebo-like) version to compare effects.See study design

What are the potential side effects?

tDCS may cause mild side effects including itching, tingling or burning sensation at the electrode sites during application. There might also be fatigue or headaches following treatment but these are generally considered rare and mild.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have long-term symptoms from COVID-19, like 'brain fog' and memory issues.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in EEG P300 event-related potential

Change in inhibitory control

Change in processing speed

Side effects data

From 2012 Phase 3 trial • 60 Patients • NCT01649232

10%

headache

10%

headedness / dizziness

fatigue or nausea

100%

80%

60%

40%

20%

Study treatment Arm

Active tDCS

Controls

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Active tDCSExperimental Treatment1 Intervention

This group will receive daily active stimulation (2 mA) to the left dorsolateral prefrontal cortex for 4 weeks through a home-based tDCS device in remotely-supervised 30-min sessions.

Group II: Sham tDCSPlacebo Group1 Intervention

This group will receive daily sham stimulation to the left dorsolateral prefrontal cortex for 4 weeks through a home-based tDCS device in remotely-supervised 30-min sessions.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Active tDCS

2012

Completed Phase 3

~1150

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor

2,929 Previous Clinical Trials

13,198,265 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study open to individuals younger than 20 years of age?

"Patients must meet the age requirements of this trial, which stipulates an upper limit of 65 years old and a lower boundary of 18 years."

Answered by AI

Are there any specified eligibility requirements for prospective participants of this research?

"This trial aims to recruit 40 individuals aged 18-65 with post-acute sequelae of covid-19. To be eligible for the study, applicants must possess capacity for informed consent and an established diagnosis of PASC based on a past COVID infection that has left them with lingering symptoms like 'brain fog', confusion, short-term memory deficits, trouble concentrating, delirium, and multitasking difficulties."

Answered by AI

Is access to this research initiative currently available for participants?

"Affirmative. On clinicaltrials.gov, it is evident that this medical experiment was first advertised on June 1st 2022 and has been recruiting ever since then; the last edit occurred on August 30th 2022. The research team needs to locate 40 individuals from a single trial site."

Answered by AI

To what capacity has enrollment for this experiment reached?

"Affirmative. Records on clinicaltrials.gov reveal that this trial, which launched June 1st 2022, is currently enrolling participants. 40 patients must be sourced from a single site for the study to continue."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

Hamdi Eryilmaz, PhD 2022. "Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05092516.